Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Raises $74M in Public Offering

NEW YORK (GenomeWeb News) – Luminex has closed its public offering of 4,025,000 shares of common stock, including the over-allotment option of 525,000 shares, raising roughly $74.3 million in net proceeds.
 
The offering was priced at $19.91 per share, which was Luminex’s closing price on June 24. In late Monday afternoon trade, the firm’s shares were down .5 percent at $20.68.
 
Luminex said in its preliminary prospectus for the offering that net proceeds will be used for general corporate purposes, including research and development, potential acquisitions of, or investments in, companies and technologies, capital expenditures, and additions to working capital.
 
JPMorgan and UBS are joint book-running managers for the offering, with Avondale Partners, Canaccord Adams, Leerink Swann acting as co-managers.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.